Home › Multiple Myeloma › Oregon › Portland
Pag-aaral pangklinika para sa Multiple Myeloma sa Portland, OR
Isang pag-aaral para sa Multiple Myeloma ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Portland. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Nagre-recruitPhase 3
- Research Site, Portland
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 3
- Oregon Health And Science University, Portland
Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
Nagre-recruitObservasyonal na pag-aaral
- OHSU Knight Cancer Institute, Portland
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Nagre-recruitPhase 2
- Providence Health & Services, Portland
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 2
- Oregon Health and Science University, Portland
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Nagre-recruitPhase 1/2
- Oregon Health and Science University /ID# 272282, Portland
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
Nagre-recruitPhase 1
- Providence Portland Medical Center, Portland
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Nagre-recruitPhase 3
- Research Site, Portland
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
Nagre-recruitPhase 2
- Oregon Health & Science University, Portland
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Nagre-recruitPhase 3
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Providence Willamette Falls Medical Center, Oregon City · 12 mi ang layo
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 1/2
- Oregon Health and Science University (OHSU) Marquam Hill Campus, Portland
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
Nagre-recruitObservasyonal na pag-aaral
- Local Institution - 0016, Portland
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
- Oregon Health Sciences University, Portland
Pag-aaral para sa Multiple Myeloma sa ibang lungsod
- New York City, NY60 pag-aaral
- Boston, MA42 pag-aaral
- Atlanta, GA41 pag-aaral
- Houston, TX38 pag-aaral
- Durham, NC37 pag-aaral
- Nashville, TN32 pag-aaral
- Denver, CO27 pag-aaral
- Rochester, MN24 pag-aaral
- St. Louis, MO24 pag-aaral
- Columbus, OH24 pag-aaral
- Baldwin Park, CA23 pag-aaral
- Chicago, IL22 pag-aaral
Iba pang pag-aaral sa Portland
- Non-Small Cell Lung Cancer46 pag-aaral
- Kanser (lahat ng uri)34 pag-aaral
- Kanser sa Prostate33 pag-aaral
- Kanser sa Suso33 pag-aaral
- Metastatic Cancer29 pag-aaral
- Colorectal Cancer28 pag-aaral
- Kanser sa Ovary27 pag-aaral
- Kanser sa Baga26 pag-aaral
- Acute Myeloid Leukemia25 pag-aaral
- Kanser ng Endometrium24 pag-aaral
- Squamous Cell Carcinoma ng Ulo at Leeg19 pag-aaral
- Kanser sa Pancreas19 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.